SARS-CoV-2 Mpro-IN-47 

SARS-CoV-2 Mpro-IN-47 is an orally active SARS-CoV-2 Mpro reversible covalent Inhibitor. SARS-CoV-2 Mpro-IN-47 shows potent antiviral activity against several clinical variants of SARS-CoV-2. SARS-CoV-2 Mpro-IN-47 can be used for the research of infection, such as SARS-CoV-2^[1].

SARS-CoV-2 Mpro-IN-47 (Compound 18) shows inhibitory activities against SARS-CoV-2, 229E and MERS virus with IC₅₀ values of 0.008, 0.01 and 0.11 μM^[1].
SARS-CoV-2 Mpro-IN-47 shows antiviral activity against USA-WA1/2020, alpha, beta, delta, and omicron variants with EC₅₀ ranging from 0.003 to 0.15μM^[1].
SARS-CoV-2 Mpro-IN-47 does not inhibit (IC₅₀ > 10 μM) host cell proteases, including various cysteine proteases, serine proteases, and aspartyl proteases^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SARS-CoV-2 Mpro-IN-47 (Compound 18) (75-300 mg/kg, p.o., twice a day for 4 days) reduces lung virus titers in SARS-CoV-2-infected mice models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

600.79

C₃₃H₅₂N₄O₆

O=C(N[C@H](C(C(NC1CC1)=O)=O)C[C@H]2C(NCCC2)=O)[C@H](CC3CCC3)C(C)C([C@@H](C4CCCC4)NC(C(C)(C)C)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tan QW, et al. Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity. J Med Chem. 2025 Aug 28;68(16):17087-17102.  [Content Brief]